Table 1.
Patient demographics and clinical characteristics.
| Characteristic | N | Overall, N = 357a | No PG, N = 347a | PG present, N = 10a | P valueb |
|---|---|---|---|---|---|
| Sex = male | 357 | 215 (60) | 211 (61) | 4 (40) | .205 |
| Race | 357 | >.999 | |||
| White, not Hispanic | 325 (91) | 315 (91) | 10 (100) | ||
| White, Hispanic | 12 (3) | 12 (4) | 0 (0) | ||
| Black, not Hispanic | 7 (2) | 7 (2) | 0 (0) | ||
| Other | 13 (4) | 13 (4) | 0 (0) | ||
| Age at UC diagnosis, years | 351 | 27.0 (20.3, 36.9) | 26.5 (20.2, 37.0) | 31.3 (26.0, 33.3) | .257 |
| Pre-colectomy biologic treatment | 345 | 126 (37) | 123 (37) | 3 (30) | .800 |
| Medically refractory | 288 (88) | 280 (88) | 8 (100) | ||
| Dysplasia | 38 (12) | 38 (12) | 0 (0) | ||
| Time between UC diagnosis and colectomy, years | 346 | 5.2 (2.0, 11.8) | 5.8 (2.0, 12.0) | 2.7 (0.8, 3.9) | .163 |
| Age at colectomy | 352 | 35.6 (27.0, 45.8) | 35.5 (27.0, 45.7) | 35.9 (31.8, 46.2) | .795 |
| Surgical approach | 352 | .173 | |||
| 1-stage | 28 (8) | 28 (8) | 0 (0) | ||
| 2-stage | 145 (41) | 143 (42) | 2 (20) | ||
| Modified 2-stage | 60 (17) | 56 (16) | 4 (40) | ||
| 3-stage | 119 (34) | 115 (34) | 4 (40) | ||
| Pre-colectomy tobacco use | 348 | >.999 | |||
| Active | 34 (10) | 33 (10) | 1 (10) | ||
| Former | 96 (28) | 93 (27) | 3 (30) | ||
| Never | 218 (63) | 212 (63) | 6 (60) | ||
| Post-colectomy tobacco use | 353 | >.999 | |||
| Active | 38 (11) | 37 (11) | 1 (10) | ||
| Former | 102 (29) | 99 (29) | 3 (30) | ||
| Never | 213 (60) | 207 (60) | 6 (60) | ||
| IBD family history | 352 | 88 (25) | 87 (25) | 1 (10) | .462 |
| PSC | 357 | 38 (11) | 38 (11) | 0 (0) | .608 |
| Follow-up since IPAA, y | 357 | 10.7 (4.4, 18.3) | 10.9 (4.4, 18.4) | 7.4 (3.5, 15.4) | .423 |
Abbreviations: IBD, inflammatory bowel disease; IPAA, ileal pouch anal anastomosis; IQR, interquartile range; PG, pyoderma gangrenosum; UC, ulcerative colitis.
a n (%); Median (IQR).
bFisher’s exact test; Wilcoxon rank-sum test.